30. Consolidated companies as of 31 December 2019

Notes to the consolidated financial statements

Name of the subsidiary

Country

% voting right
Galapagos NV
(directly or indirectly through subsidiaries)

Change in % voting
right previous
period
(2019 vs 2018)

Biofocus DPI AG in liquidation

Switzerland

100%

 

Galapagos Biopharma Belgium BV

Belgium

100%

100%

Galapagos Biopharma Netherlands B.V.

The Netherlands

100%

100%

Galapagos Biopharma Spain S.L.U

Spain

100%

100%

Galapagos Biopharma Italy S.r.l.

Italy

100%

100%

Galapagos Biopharma Germany GmbH

Germany

100%

100%

Galapagos Biotech Ltd.

United Kingdom

100%

 

Galapagos BV

The Netherlands

100%

 

Galapagos GmbH

Switzerland

100%

 

Galapagos, Inc.

United States

100%

 

Galapagos NV

Belgium

Parent company

 

Galapagos Real Estate 1 BV

Belgium

100%

 

Galapagos Real Estate 2 BV

Belgium

100%

 

Galapagos Real Estate Netherlands B.V.

The Netherlands

100%

100%

Galapagos SASU

France

100%

 

Fidelta d.o.o.

Croatia

100%

 

Xenometrix, Inc. in liquidation

United States

100%

 

In the course of 2019 we incorporated the following new legal entities: Galapagos Biopharma Belgium BV (Mechelen, Belgium), Galapagos Biopharma Netherlands B.V. and Galapagos Real Estate Netherlands B.V. (Leiden, the Netherlands); Galapagos Biopharma Germany GmbH (München, Germany); Galapagos Biopharma Spain S.L.U. (Madrid, Spain) and Galapagos Biopharma Italy S.r.l. (Milan, Italy).

There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities, of one of the group’s subsidiaries.